Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of CS0159 Tablets in Subjects With Mild (Child-Pugh: Class A), Moderate (Child-Pugh: Class B) Hepatic Impairment, and Normal Hepatic Function
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Linafexor (Primary)
- Indications Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Cascade Pharmaceuticals
- 10 Apr 2025 Status changed from not yet recruiting to recruiting.
- 25 Mar 2025 New trial record